Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Depreciation & Amortization - Total (2024 - 2026)

Maxcyte has reported Depreciation & Amortization - Total over the past 2 years, most recently at $1.1 million for Q4 2025.

  • Quarterly Depreciation & Amortization - Total changed 0.19% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, changed 0.09% year-over-year, with the annual reading at $4.3 million for FY2025, 0.65% down from the prior year.
  • Depreciation & Amortization - Total was $1.1 million for Q4 2025 at Maxcyte, roughly flat from $1.1 million in the prior quarter.
  • Over five years, Depreciation & Amortization - Total peaked at $1.1 million in Q2 2025 and troughed at $1.1 million in Q4 2025.